We have located links that may give you full text access.
Stable IL-1-Activation in an Inflammasome Signalling Model Depends on Positive and Negative Feedbacks and Tight Regulation of Protein Production.
INTRODUCTION: NLRP3-dependent inflammasome signalling is a key pathway during inflammatory processes and its deregulation is implicated in several diseases. NLRP3-inflammasome pathway activation leads to the rapid, hosphorylation-driven NFB-pathway signalling, subsequently proceeds via lower transcription/translation process for producing pro-enzymes, and finally leads to the medium-speed enzymatic activation of the central inflammatory ediator IL-1 [1]. We here were interested how the timing of the rate-limiting step of transcription/translation and the presence of a positive and negative auto-regulation would pose conditions for meaningful and stable IL-1-activation.
METHODS: We extracted the essential topology of the inflammasome pathway network using a linear chain of first order reaction and a second order reaction for inhibitory feedback. We then performed an analytical treatment of the resulting ODE set to obtain closed-form formulae. We therefore looked for the steady states and characterised their stability by using a Jacobian-based, local analysis. We employed the Small Gain Theorem from Control Theory as recently applied by us [2] and the Gershgorin Circle Theorem to obtain mathematically exact conditions for a positive on state and stabilities for on and off steady states.
RESULTS: We identified an on- and one off- steady state whose properties we characterised in terms of the kinetic parameters by closed-form formulae. We found that under the assumption of a first-order information flow through the network the existence of a biologically reasonable ON steady state required the simultaneous presence of the positive and the negative feedback. Assuming non-competitivity between IL-1 entities binding to different receptors, we found that a minimum kinetics for protein production is required to sustain a steady state with IL-1 activation. Assuming competitivity between IL-1 entities introduced additional restrictions on the maximum protein production speed to guarantee a biologically reasonable ON steady state. Finally, for both models we ruled out bistability, suggesting that IL- 1 activation would undergo a smooth change upon alterations of its parameters.
CONCLUSION: Exemplified by the core pathway of NLRP3-inflammasome signalling, we here demonstrate that a mostly linear activation cascade containing an intermediate rate limiting step poses kinetic restrictions on this step and requires positive and negative autoregulation for obtaining a meaningful ON steady state. Due to the generality of our framework, our results are important for a wide class of receptor mediated-pathways, where a fast initial phosphorylation cascade is followed by a (slower) transcriptional response and subsequent autoregulation. Our results may further provide important design principles for synthetic biological networks involving biochemical activation and transcription/translation, by relating timing considerations and autoregulation to stable pathway activation.
METHODS: We extracted the essential topology of the inflammasome pathway network using a linear chain of first order reaction and a second order reaction for inhibitory feedback. We then performed an analytical treatment of the resulting ODE set to obtain closed-form formulae. We therefore looked for the steady states and characterised their stability by using a Jacobian-based, local analysis. We employed the Small Gain Theorem from Control Theory as recently applied by us [2] and the Gershgorin Circle Theorem to obtain mathematically exact conditions for a positive on state and stabilities for on and off steady states.
RESULTS: We identified an on- and one off- steady state whose properties we characterised in terms of the kinetic parameters by closed-form formulae. We found that under the assumption of a first-order information flow through the network the existence of a biologically reasonable ON steady state required the simultaneous presence of the positive and the negative feedback. Assuming non-competitivity between IL-1 entities binding to different receptors, we found that a minimum kinetics for protein production is required to sustain a steady state with IL-1 activation. Assuming competitivity between IL-1 entities introduced additional restrictions on the maximum protein production speed to guarantee a biologically reasonable ON steady state. Finally, for both models we ruled out bistability, suggesting that IL- 1 activation would undergo a smooth change upon alterations of its parameters.
CONCLUSION: Exemplified by the core pathway of NLRP3-inflammasome signalling, we here demonstrate that a mostly linear activation cascade containing an intermediate rate limiting step poses kinetic restrictions on this step and requires positive and negative autoregulation for obtaining a meaningful ON steady state. Due to the generality of our framework, our results are important for a wide class of receptor mediated-pathways, where a fast initial phosphorylation cascade is followed by a (slower) transcriptional response and subsequent autoregulation. Our results may further provide important design principles for synthetic biological networks involving biochemical activation and transcription/translation, by relating timing considerations and autoregulation to stable pathway activation.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app